Effect of Diacylglycerol Oil on Risk Factors of Type 2 Diabetes and Complicating Disease, and Mechanism

Zhejiang University0 sites127 target enrollmentMarch 1, 2013

ConditionsInsulin Sensitivity Type 2 Diabetes Cardiovascular Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Insulin Sensitivity
Sponsor: Zhejiang University
Enrollment: 127
Primary Endpoint: insulin resistance
Status: Completed
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Diacylglycerol oil has been shown to lower postprandial and fasting serum triacylglycerol levels and reduce body fat. The investigators hypothesize that replacing dietary fat with diacylglycerol oil reduces excess body fat in type 2 diabetic patients and that diacylglycerol oil has a beneficial effect on cardiovascular risk factors in Chinese type 2 diabetic patients.

Registry

clinicaltrials.gov

Start Date

March 1, 2013

End Date

February 2006

Last Updated

13 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Zhejiang University

Responsible Party

Principal Investigator

Duo li

Professor

Zhejiang University

Eligibility Criteria

Inclusion Criteria

•Type 2 diabetic patients, blood sugar levels were stabilized between 7.0-10.0 mmol/L
•Male, aged 40 - 70 years old, Female, aged post-menopausal - 70 years old.
•Overweight/obese patients (BMI 25 - 40 kg/m2)
•Currently under diet therapy for diabetes mellitus
•Understands the procedures and willing to participate in the study

Exclusion Criteria

•Patients who unwilling to give informed consent
•Type 1 diabetic patients
•Familial hyperlipemia patients or blood triacylglycerol concentration \> 400 mg/dl
•Patients with a history of cardiovascular disease and/or arteriosclerotic disease
•Patients with a history of cerebrovascular disease
•Patients with serious hepatic disease and/or renal disease
•Patients with malignancy
•Participation in another clinical study within 30 days prior to screening period.
•Has a condition the doctor in charge believes would interfere with evaluation of the subject, or may put subject at undue risk